GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.

 GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.

GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.

  Shots:
  •  With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety
  • To identify specific subgroups population to develop targeted treatments
  • GSK is initially planning to leverage 23andMe databases for the development of its   LRRK2i molecule in preclinical stage targeting Parkinson’s

Click here to read full press release/ article | Ref: GSK | Image: widdowquinn/Flickr

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post